While the financial details of the contract were not disclosed, the sale includes associated product and process technology, intellectual property and trademarks.
The ownership of the Mirfield and
The Dowpharma businesses in the
Peter Davies, president of Dow’s Designed Polymers and Latex business, said: ‘Dr Reddy’s core operations and capabilities are strongly aligned with the specialty chiral and biocatalysis custom manufacturing business, so it is well equipped to help these businesses reach their full potential. Our priority now is working closely with Dr Reddy’s to continue to ensure a seamless transition for our customers.’